Search results for "cost-effectivene"

showing 10 items of 76 documents

Screening for Early Detection of Asymptomatic Coronary Artery Disease (Secondary Prevention): An Approach to Cost/Benefit and Cost/Effectiveness Anal…

1983

Classification of different types of preventive measures for ischemic heart disease (IHD) has been much debated. In the classical use of terms “primary prevention” (prevention of occurrence) includes removal of risk factors in otherwise healthy individuals, while the attempts to change diet and life style in the very early age, in order to avoid the acquisition of risk factors, has been called “preprimary prevention” or “early prevention.”

Secondary preventionmedicine.medical_specialtybusiness.industryEarly detectionCost-effectiveness analysisDiseasemedicine.diseaseAsymptomaticCoronary artery diseaseInternal medicinemedicineCardiologyCost benefitmedicine.symptomIntensive care medicineIschemic heartbusiness
researchProduct

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2013

We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…

Settore MED/12 - Gastroenterologiamedicine.medical_specialtyCirrhosisHepatologySofosbuvirCost effectivenessbusiness.industryGastroenterologyPharmacologyHepatologycost-effectiveness sofosbuvir boceprevir telaprevir chronic hepatitis Cmedicine.diseaseTelaprevirchemistry.chemical_compoundchemistryTolerabilityBoceprevirInternal medicineGenotypemedicineSettore SECS-S/05 - Statistica SocialeSettore SECS-S/01 - Statisticabusinesshealth care economics and organizationsmedicine.drugDigestive and Liver Disease
researchProduct

PGI19 Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists or Sucralfate: A Cost-Effectiveness Analysis

2011

SucralfateHistamine H2 receptorbusiness.industryAnesthesiaStress ulcerHealth PolicyPublic Health Environmental and Occupational HealthMedicineCost-effectiveness analysisbusinessmedicine.diseasehealth care economics and organizationsmedicine.drugValue in Health
researchProduct

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2020

Abstract: Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods Th…

Systems AnalysisGoutCost effectiveness030204 cardiovascular system & hematologyGlobal HealthGLOMERULAR-FILTRATION-RATEGlobal Burden of DiseaseCOST-EFFECTIVENESS0302 clinical medicineCause of DeathPrevalenceGlobal healthDiabetic NephropathiesRegistries030212 general & internal medicineSUB-SAHARAN AFRICA11 Medical and Health SciencesIncidenceMortality rate1. No povertyGeneral MedicineHälsovetenskaperGBD Chronic Kidney Disease CollaborationCKD-EPI EQUATION3. Good healthEuropeCardiovascular Diseases/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingQuality-Adjusted Life YearsLife Sciences & BiomedicineAsiaOceania195 COUNTRIESATHEROSCLEROSIS RISKCARDIOVASCULAR OUTCOMESRisk AssessmentArticle03 medical and health sciencesMedicine General & InternalSDG 3 - Good Health and Well-beingRISK-FACTORGeneral & Internal MedicineEnvironmental healthHealth SciencesmedicineHumansGBD chronic kidney diseaseMortalityRisk factorRenal Insufficiency ChronicDisease burdenQMScience & TechnologyAustralasiabusiness.industryPERIPHERAL ARTERIAL-DISEASEBayes Theoremmedicine.diseaseHealth SurveysQuality-adjusted life yearRENAL-DISEASELatin AmericaYears of potential life lostAfricaNorth AmericaHuman medicinebusinessRCKidney disease
researchProduct

Advanced Monitoring of Rotor Broken Bar in Double Squirrel Cage Induction Machines Based on Wavelet Analysis

2012

The diagnosis of induction machine faults is commonly realized through Motor Current Signature Analysis (MCSA), i.e. by classical spectrum analysis of the input currents. In case of large or double cage induction motors, rotor broken bars fault detection based on sideband current components may fail due to the presence of inter bar currents that reduce the degree of rotor asymmetry, leading to reduced relevance of these spectral components. But inter bar currents produce core vibrations in the axial direction, which can be detected using vibration analysis techniques, in order to overcome the limits of the classical MCSA for these purposes. In this paper, an advanced use of the Discrete wav…

Transverse flux permanent magnet machines claw pole topology soft magnetic composite finite element analysis cost-effectiveness assemblyTransverse flux permanent magnet machines claw pole topology soft magnetic composite finite element analysis cost-effectiveness assembly.Settore ING-IND/32 - Convertitori Macchine E Azionamenti Elettrici
researchProduct

Kosteneffektivitätsanalyse der Versorgung von Kataraktpatienten mit monofokalen Intraokularlinsen aus Sicht der Leistungserstatter

2003

BACKGROUND Data on the cost effectiveness of cataract surgery with respect to the German statutory health insurance system are hardly available. Hence the increase in visual acuity as primary efficacy endpoint, order of posterior capsule opacification as primary complication endpoint and direct cost for supplementation with monofocal intraocular lenses have been assessed via meta-analyses to evaluate the procedure's cost effectiveness from the perspective of the German statutory health insurance system. MATERIAL AND METHODS Using the medical internet database MEDLINE two meta-analyses on publications between 1995 and 2002 were carried out, one estimating the gained increase in visual acuity…

Visual acuitygenetic structuresCost effectivenessbusiness.industrymedicine.medical_treatmentEye diseaseOutpatient surgeryIntraocular lensCataract surgerymedicine.diseaseeye diseasesOphthalmologyInterquartile rangeMedicineOptometrymedicine.symptombusinessIncremental cost-effectiveness ratioKlinische Monatsblätter für Augenheilkunde
researchProduct

The 10‐year treatment outcome of open dialogue‐based psychiatric services for adolescents: A nationwide longitudinal register‐based study

2022

Aim: To evaluate the 10-year treatment outcomes and cost-effectiveness of adolescents' mental health treatment initiated under the social network-oriented open dialogue (OD) approach. -- Methods: This longitudinal register-based study included all persons who, for the first time, received psychiatric treatment in Finland during the period 1 January 2003–31 December 2008, and who were aged 13–20 at onset (n = 44 868). The OD group included all persons whose treatment commenced in the Western Lapland catchment area (n = 780), this being the only region in Finland where OD covered the entire mental healthcare service at the time of inclusion. The comparison group (CG) included the rest of Finl…

avoimen dialogin hoitomallichild and adolescent psychiatryhoitovastelong-term follow-upkustannustehokkuuspitkittäistutkimusPsychiatry and Mental healthVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Psykiatri barnepsykiatri: 757nuoretpsykiatrinen hoitocohort studyfamily therapymielenterveyspalvelutPshychiatric Mental Healthcost-effectivenesskohorttitutkimusBiological PsychiatryEarly Intervention in Psychiatry
researchProduct

Financial Aspects of Cervical Disc Arthroplasty: A Narrative Review of Recent Literature

2020

Recently, there has been significant interest in understanding the cost-effectiveness of treatments in spine surgery as health care systems in the United States move toward value-based care and alternative payment models. Previous studies have shown comparable outcomes of cervical disc arthroplasty (CDA) and anterior cervical discectomy fusion; however, there is a lack of consensus on the cost-effectiveness of CDA to support full adoption. Evidence of the limitations of these cost-analysis studies also exists in the literature, including industry funding, potential selection bias, and varying methods of calculating value. The goal of this narrative review is to provide an overview of the co…

cervical disc arthroplastyTotal Disc Replacementmedicine.medical_specialtyCost effectivenessCost-Benefit Analysismedia_common.quotation_subjectmedicine.medical_treatmentAnterior cervical discectomy and fusionIntervertebral Disc Degeneration03 medical and health sciences0302 clinical medicineSpine surgeryHealth careHumansMedicinePatient Reported Outcome MeasuresRadiculopathyIntensive care medicinecost-effectivenesshealth care economics and organizationsmedia_commonSelection biasbusiness.industryArthroplastyUnited StatesSpinal Fusioncost-analysis studie030220 oncology & carcinogenesisCervical VertebraeCosts and Cost AnalysisSurgeryNarrative reviewQuality-Adjusted Life YearsNeurology (clinical)businessCervical discSpinal Cord Compression030217 neurology & neurosurgeryanterior cervical discectomy and fusionDiskectomy
researchProduct

Early Treatment in HCV: Is it a Cost-Effective Option from the Italian Perspective?

2016

Background: The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing HCV-infected patients.Methods: The incremental cost-utility analysis was carried out to quantify the benefits of the early treatment approach in HCV subjects. A Markov simulation model including direct and indirect costs and health outcomes was developed from Italian National Healthcare Service and societal perspective. 5,000 Monte Carlo simulations were performed on two distinct scenarios: Standard of Care (SoC) which includes 14.000 Genotype 1 patients in Italy treated with innovative interferon-free in the Fibrosis stage 3 and 4 (F3-F4) v…

education.field_of_studymedicine.medical_specialtyActuarial sciencebusiness.industryPopulationTime horizonIndirect costsSystematic reviewEpidemiologyHealth careMedicineeducationbusinessIncremental cost-effectiveness ratiohealth care economics and organizationsReimbursementSSRN Electronic Journal
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct